RESUMO
Objective To compare and explore the efficacy of regional citrate anticoagulation therapy and regional heparin anticoagulation therapy in continuous renal replacement therapy ( CRRT) of acute kidney injury ( AKI) patients with risk of bleeding by an retrospective study. Methods A total of 96 AKI patients with risk of bleeding were collected retrospectively and treated with CRRT. All the patients were divided into two groups:regional citrate group ( n=50) and regional heparin group ( n=46) . APTT, level of Ca2+, pH value, levels of HCO-3 and Na+, time of blood filter using and incidence of adverse events were compared between the two groups. Results Percentage of hypernatremia, metabolic alkalosis and elevation of transaminase in regional citrate group were 2.3%, 6.1%, 1.9%, respectively, those in the regional heparin group were 1.6%, 0.9%, 1.6%, respectively. The time of blood filter using in regional citrate group and regional heparin group were (70.0±5.3) h and (48.0±2.7) h, respectively (P<0.05). Incidence of bleeding event in regional citrate group and regional heparin group were 3.8% and 13.0%, respectively (P<0.05). Conclusion In patients with coagulation disorders or bleeding risk undergoing CRRT, regional citrate anticoagulation therapy is safer and more effective, and worthy of promotion.
RESUMO
Objective To compare and explore the efficacy of regional citrate anticoagulation therapy and regional heparin anticoagulation therapy in continuous renal replacement therapy ( CRRT) of acute kidney injury ( AKI) patients with risk of bleeding by an retrospective study. Methods A total of 96 AKI patients with risk of bleeding were collected retrospectively and treated with CRRT. All the patients were divided into two groups:regional citrate group ( n=50) and regional heparin group ( n=46) . APTT, level of Ca2+, pH value, levels of HCO-3 and Na+, time of blood filter using and incidence of adverse events were compared between the two groups. Results Percentage of hypernatremia, metabolic alkalosis and elevation of transaminase in regional citrate group were 2.3%, 6.1%, 1.9%, respectively, those in the regional heparin group were 1.6%, 0.9%, 1.6%, respectively. The time of blood filter using in regional citrate group and regional heparin group were (70.0±5.3) h and (48.0±2.7) h, respectively (P<0.05). Incidence of bleeding event in regional citrate group and regional heparin group were 3.8% and 13.0%, respectively (P<0.05). Conclusion In patients with coagulation disorders or bleeding risk undergoing CRRT, regional citrate anticoagulation therapy is safer and more effective, and worthy of promotion.
